Market
FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
[ad_1]
The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.
Reata’s RETA stock was halted in after-hours trading on Tuesday in advance of the FDA’s decision.
The drug, omaveloxolone, which is now called Skyclarys,…
[ad_2]
Source link